TerminatedEarly Phase 1

Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)

Stopped: lack of efficacy/futility

United States6 participantsStarted 2023-02-15

Plain-language summary

The purpose of the study is to evaluate the safety and effectiveness of siltuximab for participants being treated for large granular lymphocytic leukemia (LGLL).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. severe neutropenia less than 500/mm³, OR
✓. neutropenia associated with recurrent infection, OR
✓. symptomatic anemia with Hemoglobin \< 9 g/dL, OR
✓. transfusion-dependent anemia with transfusion needs \>= 1 u per month, OR
✓. severe thrombocytopenia \<20,000/mm³, OR
✓. thrombocytopenia \<50,000/mm³ with bleeding.

What they're measuring

Overall Response Rate

Timeframe: Up to 30 months

Trial details

NCT IDNCT05316116

SponsorH. Lee Moffitt Cancer Center and Research Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-10-18

View on ClinicalTrials.gov More Large Granular Lymphocyte Leukemia trials